Sebastien Morisot, PhD Post-Doctoral Fellow smorisot@som.umaryland.edu
Education:
BS in Cell Biology from Universite Paris-XI MS in Cancer Biology from Universite Paris-XI Ph.D. in Cancer Biology from Universite Paris-XI (exchange program with Johns Hopkins University)
Research Interests
My main project focuses on the determination of the frequency of leukemia stem cells (LSCs) and their involvement in pediatric precursor B acute lymphoblastic leukemia (ALL) patients. This highly translational project involves the establishment of in vivo mouse models using highly immuno-compromised animals, providing a relevant way to address fundamental questions as well as for the testing of novel drugs in collaboration with NIH.
Laboratory Experiences
Retroviral Vectors Construction and Human Liver Cells Infection; Hopital A. Beclere, Clamart, France (2002) Purification of The Proteins Binding to a New Signalling Adaptor, SLY, in TLymphocytes; University of Cambridge, Cambridge, UK (2003) Functional and Phenotypical Characterization of Skeletal Muscle SP Cell;s Genopole, Evry, France (2004) Determination of the Frequency of Leukemia Stem Cells in Childhood Precursor B Acute Lymphoblastic Leukemias; Johns Hopkins University School of Medicine, Baltimore, MD (2004-2009) The effects of Immunotoxins on Childhood Precursor B Cell Aucute Lymphoblastic Leukemias. University of Maryland School of Medicine, Baltimore, MD (Present-)
Publications
Georgantas, RW, 3rd, Hildreth, R., Morisot, S., Alder, J., Liu, CG, Heimfeld, S., Calin, GA, Croce, CM, and Civin, CI. (2007). CD34+ hematopoietic stem-progenitor cell microRNA expression and function: a circuit diagram of differentiation control. Proc Natl Acad Sci U S A 104, 2750-2755. Alder, JK, Georgantas, RW, 3rd, Hildreth, RL, Kaplan, IM, Morisot, S., Yu, X, McDevitt, M, and Civin, CI. (2008). Kruppel-like factor 4 is essential for inflammatory monocyte differentiation in vivo. J Immunol 180, 5645-5652. Bohana-Kashtan, O, Morisot, S., Hildreth, R, Brayton, C, Levitsky, HI, and Civin, CI. Selective reduction of Graft versus Host Disease-mediating human T cells by ex vivo treatment with soluble Fas ligand. J Immunol. In press.